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Background
Hereditary non-polyposis colorectal cancer or Lynch
syndrome (LS) is characterized by mismatch repair
(MMR) loss of function. The aim of this study was to
compare the clinical characteristics and family histories
of MMR mutation-positive and mutation-negative
patients with tumor studies suggestive for LS.
Methods
Patients with loss of MLH1/MSH2 on immunohisto-
chemistry (IHC) or with microsatellite instability (MSI)-
high tumors were identified in our institutional LS
database (February 1992–June 2010). Patients who sub-
sequently underwent MLH1/MSH2 mutation analysis
were reviewed. Patients with no identifiable MLH1
germline mutation were excluded if MLH1 promoter
methylation was present or not assessed. Patients with
variants of uncertain significance were also excluded.
Demographics, clinical characteristics, mutational test-
ing, and family histories of patients were analyzed.
Results
Of 92 patients with informative tumor studies who
underwent germline mutation testing with unequivocal
results, 61 (58.7%) were mutation-positive and 31
(29.8%) were mutation-negative. The mutation detection
rate for MLH1 and MSH2 was 51.2% and 78.4%, respec-
tively. A significant difference (p=0.006) in the propor-
tion of MLH1 and MSH2 defects was found between
mutation groups (Table 1).
Colorectal cancer (CRC) was diagnosed in 76 patients
(82.6%; Table 1). Mutation-positive patients had a
younger mean age of CRC diagnosis (43.4 vs. 50.0,
p=0.011). Endometrial and other LS cancers were diag-
nosed in 36.0% and 29.5% of mutation-positive patients
and 27.8% and 16.1% of mutation-negative patients,
respectively. Clinical criteria were more sensitive in
identifying MMR-positive than MMR-negative families
(Amsterdam I: 42.6% vs. 9.7%, p=0.001; Amsterdam II:
60.7% vs. 12.9%, p<0.001; Bethesda: 93.4% vs. 67.7%,
p=0.004). Mutation-positive patients meeting at least
one of these criteria on average had more than twice as
many affected relatives (3.7 vs. 1.5, p=<0.001).
Discussion
In this population of patients with presumptive LS diag-
noses based upon tumor studies, mutation-negative
patients had significant personal cancer histories
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Table 1
Gene CRC
MLH1 MSH2 Diagnosed Age at diagnosis (SD) Proximal location Synchronous / metachronous
Mutation Positive n=61 21 (34.4%) 40 (65.6%) 52 (85.2%) 43.4 (11.5) 25 (48.1%) 17 (32.7%)
Mutation Negative n=31 20 (64.5%) 11 (35.5%) 24 (77.4%) 50.0 (11.7) 15 (62.5%) 5 (20.8%)
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concerning for LS with slightly later ages of initial LS
cancer and CRC diagnosis. However, their family
histories were significantly less suggestive as nearly
one-third of patients were missed by Bethesda criteria
and over 85% by Amsterdam I/II criteria. This suggests
that both established clinical criteria and germline
mutation analysis may fail to detect a significant number
of patients with presumed LS and supports the use of
routine MSI/IHC analyses to identify these otherwise
undetectable high-risk families.
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